



July 29, 2015

## **Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015**

SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2015 at 5:00 p.m. ET to report its second quarter 2015 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 93536859. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). The archived webcast will be available on the Company's website beginning approximately two hours after the event.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company's lead product candidate, PROHEMA®, is an *ex vivo* programmed hematopoietic cellular therapeutic, which is currently in clinical development in patients undergoing hematopoietic stem cell transplantation. The Company is also developing a PD-L1 programmed immuno-regulatory cellular therapeutic for the treatment of autoimmune diseases and is leveraging its proprietary induced pluripotent stem cell platform to develop natural killer cell and T cell cancer immunotherapeutics. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

CONTACT: Jesse Baumgartner, Stern Investor Relations, Inc.

212.362.1200, [jesse@sternir.com](mailto:jesse@sternir.com)